BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boss C, Brisbare-Roch C, Jenck F. Biomedical application of orexin/hypocretin receptor ligands in neuroscience. J Med Chem 2009;52:891-903. [PMID: 19199652 DOI: 10.1021/jm801296d] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Oi N, Suzuki M, Terauchi T, Tokunaga M, Nakatani Y, Yamamoto N, Fukumura T, Zhang M, Suhara T, Higuchi M. Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor. J Med Chem 2013;56:6371-85. [DOI: 10.1021/jm400772t] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
2 Perrey DA, German NA, Gilmour BP, Li JX, Harris DL, Thomas BF, Zhang Y. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. J Med Chem 2013;56:6901-16. [PMID: 23941044 DOI: 10.1021/jm400720h] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
3 Boss C. Orexin receptor antagonists--a patent review (2010 to August 2014). Expert Opin Ther Pat 2014;24:1367-81. [PMID: 25407283 DOI: 10.1517/13543776.2014.978859] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
4 Lesma G, Cecchi R, Crippa S, Giovanelli P, Meneghetti F, Musolino M, Sacchetti A, Silvani A. Ugi 4-CR/Pictet–Spengler reaction as a short route to tryptophan-derived peptidomimetics. Org Biomol Chem 2012;10:9004. [DOI: 10.1039/c2ob26301g] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
5 Malherbe P, Roche O, Marcuz A, Kratzeisen C, Wettstein JG, Bissantz C. Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX 1 Antagonist SB-674042 and the Selective OX 2 Antagonist N -Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]- N -pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol 2010;78:81-93. [DOI: 10.1124/mol.110.064584] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
6 Furlong TM, Vianna DM, Liu L, Carrive P. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur J Neurosci 2009;30:1603-14. [PMID: 19811530 DOI: 10.1111/j.1460-9568.2009.06952.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
7 Liu F, Majo VJ, Prabhakaran J, Castrillion J, Mann JJ, Martinez D, Kumar JD. Radiosynthesis of [11C]BBAC and [11C]BBPC as potential PET tracers for orexin2 receptors. Bioorganic & Medicinal Chemistry Letters 2012;22:2172-4. [DOI: 10.1016/j.bmcl.2012.01.114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
8 Boss C, Roch-brisbare C, Steiner MA, Treiber A, Dietrich H, Jenck F, von Raumer M, Sifferlen T, Brotschi C, Heidmann B, Williams JT, Aissaoui H, Siegrist R, Gatfield J. Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist. ChemMedChem 2014;9:2486-96. [DOI: 10.1002/cmdc.201402258] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
9 Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang C, Roller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53:5320-32. [PMID: 20565075 DOI: 10.1021/jm100541c] [Cited by in Crossref: 242] [Cited by in F6Publishing: 217] [Article Influence: 20.2] [Reference Citation Analysis]
10 Qi X, Astle J, Kodadek T. Rapid identification of orexin receptor binding ligands using cell-based screening accelerated with magnetic beads. Mol Biosyst 2010;6:102-7. [PMID: 20024071 DOI: 10.1039/b915611a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
12 Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 2010;5:1197-214. [PMID: 20544785 DOI: 10.1002/cmdc.201000132] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
13 Dömling A, Wang W, Wang K. Chemistry and biology of multicomponent reactions. Chem Rev 2012;112:3083-135. [PMID: 22435608 DOI: 10.1021/cr100233r] [Cited by in Crossref: 1512] [Cited by in F6Publishing: 1032] [Article Influence: 151.2] [Reference Citation Analysis]
14 Menendez P, D'acquarica I, Monache GD, Ghirga F, Calcaterra A, Barba M, Macone A, Boffi A, Bonamore A, Botta B. Production of Bioactives Compounds: The Importance of Pictet-Spengler Reaction in the XXI Century. In: Cechinel-filho V, editor. Plant Bioactives and Drug Discovery. Hoboken: John Wiley & Sons, Inc.; 2012. pp. 453-87. [DOI: 10.1002/9781118260005.ch13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Christopher JA. Small-molecule antagonists of the orexin receptors. Pharm Pat Anal 2014;3:625-38. [PMID: 25489915 DOI: 10.4155/ppa.14.46] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
16 Laburthe M, Voisin T. The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol 2012;165:1678-87. [PMID: 21627633 DOI: 10.1111/j.1476-5381.2011.01510.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
17 Khan I, Singh J, Kumar V, Verma VP, Shukla M, Dhasmana A, Naruka PS, Goswami AK, Ameta KL, Khan S. A Versatile Pre and Post Ugi Modification for the Synthesis of Natural Product Inspired Fused Peptide‐Carboline Scaffolds as Potential Anti‐Leishmanial Agents. ChemistrySelect 2019;4:12260-7. [DOI: 10.1002/slct.201902441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Coleman PJ, Renger JJ. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat 2010;20:307-24. [PMID: 20180618 DOI: 10.1517/13543770903567085] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
19 Nagahara T, Saitoh T, Kutsumura N, Irukayama-Tomobe Y, Ogawa Y, Kuroda D, Gouda H, Kumagai H, Fujii H, Yanagisawa M, Nagase H. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J Med Chem 2015;58:7931-7. [PMID: 26267383 DOI: 10.1021/acs.jmedchem.5b00988] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
20 Sifferlen T, Koberstein R, Cottreel E, Boller A, Weller T, Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2. Bioorg Med Chem Lett 2013;23:3857-63. [PMID: 23719231 DOI: 10.1016/j.bmcl.2013.04.071] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
21 Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J. Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant. Clin Pharmacol Ther 2010;87:593-600. [DOI: 10.1038/clpt.2010.19] [Cited by in Crossref: 81] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
22 Kuduk SD, Winrow CJ, Coleman PJ. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders. Elsevier; 2013. pp. 73-87. [DOI: 10.1016/b978-0-12-417150-3.00006-5] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ioachimescu OC, El-Solh AA. Pharmacotherapy of insomnia. Expert Opin Pharmacother 2012;13:1243-60. [PMID: 22578014 DOI: 10.1517/14656566.2012.683860] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
24 Jiang R, Song X, Bali P, Smith A, Bayona CR, Lin L, Cameron MD, McDonald PH, Kenny PJ, Kamenecka TM. Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists. Bioorg Med Chem Lett 2012;22:3890-4. [PMID: 22617492 DOI: 10.1016/j.bmcl.2012.04.122] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
25 Perrey DA, German NA, Decker AM, Thorn D, Li JX, Gilmour BP, Thomas BF, Harris DL, Runyon SP, Zhang Y. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor. ACS Chem Neurosci 2015;6:599-614. [PMID: 25643283 DOI: 10.1021/cn500330v] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
26 Luster BR, Urbano FJ, Garcia-Rill E. Intracellular mechanisms modulating gamma band activity in the pedunculopontine nucleus (PPN). Physiol Rep 2016;4:e12787. [PMID: 27354537 DOI: 10.14814/phy2.12787] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
27 Reddy NSS, Reddy BS. Stereoselective total synthesis of almorexant. Tetrahedron Letters 2014;55:3157-9. [DOI: 10.1016/j.tetlet.2014.03.130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
28 Tripolitsiotis NP, Thomaidi M, Neochoritis CG. The Ugi Three‐Component Reaction; a Valuable Tool in Modern Organic Synthesis. Eur J Org Chem 2020;2020:6525-54. [DOI: 10.1002/ejoc.202001157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Heidmann B, Gatfield J, Roch C, Treiber A, Tortoioli S, Brotschi C, Williams JT, Bolli MH, Abele S, Sifferlen T, Jenck F, Boss C. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. ChemMedChem 2016;11:2132-46. [DOI: 10.1002/cmdc.201600175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Duguay D, Bélanger-Nelson E, Mongrain V, Beben A, Khatchadourian A, Cermakian N. Dynein light chain Tctex-type 1 modulates orexin signaling through its interaction with orexin 1 receptor. PLoS One 2011;6:e26430. [PMID: 22028875 DOI: 10.1371/journal.pone.0026430] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
31 Mangion IK, Sherry BD, Yin J, Fleitz FJ. Enantioselective Synthesis of a Dual Orexin Receptor Antagonist. Org Lett 2012;14:3458-61. [DOI: 10.1021/ol3014123] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
32 Christopher JA, Congreve MS. Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692). Expert Opinion on Therapeutic Patents 2012;23:273-7. [DOI: 10.1517/13543776.2013.749240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Luster B, D'Onofrio S, Urbano F, Garcia-Rill E. High-threshold Ca2+ channels behind gamma band activity in the pedunculopontine nucleus (PPN). Physiol Rep 2015;3:e12431. [PMID: 26109189 DOI: 10.14814/phy2.12431] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
34 Wang W, Herdtweck E, Dömling A. Polycyclic indole alkaloid-type compounds by MCR. Chem Commun (Camb) 2010;46:770-2. [PMID: 20087515 DOI: 10.1039/b917660h] [Cited by in Crossref: 56] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
35 Perrey DA, Decker AM, Zhang Y. Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability. ACS Chem Neurosci 2018;9:587-602. [PMID: 29129052 DOI: 10.1021/acschemneuro.7b00402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
36 Kim AK, Brown RM, Lawrence AJ. The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front Behav Neurosci 2012;6:78. [PMID: 23189046 DOI: 10.3389/fnbeh.2012.00078] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
37 Liu H, Dömling A. Efficient and diverse synthesis of indole derivatives. J Org Chem 2009;74:6895-8. [PMID: 19663394 DOI: 10.1021/jo900986z] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
38 Yamamoto N, Ohrui S, Okada T, Yata M, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor. Bioorganic & Medicinal Chemistry Letters 2017;27:4176-9. [DOI: 10.1016/j.bmcl.2017.07.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
39 Perrey DA, Gilmour BP, Runyon SP, Thomas BF, Zhang Y. Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists. Bioorg Med Chem Lett 2011;21:2980-5. [PMID: 21478014 DOI: 10.1016/j.bmcl.2011.03.048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
40 Zhang D, Liu J, Kang Z, Qiu H, Hu W. A rhodium-catalysed three-component reaction to access C1-substituted tetrahydroisoquinolines. Org Biomol Chem 2019;17:9844-8. [PMID: 31724684 DOI: 10.1039/c9ob02303h] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Coleman PJ, Schreier JD, Roecker AJ, Mercer SP, Mcgaughey GB, Cox CD, Hartman GD, Harrell CM, Reiss DR, Doran SM, Garson SL, Anderson WB, Tang C, Prueksaritanont T, Winrow CJ, Renger JJ. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat. Bioorganic & Medicinal Chemistry Letters 2010;20:4201-5. [DOI: 10.1016/j.bmcl.2010.05.047] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
42 Coleman PJ, Schreier JD, McGaughey GB, Bogusky MJ, Cox CD, Hartman GD, Ball RG, Harrell CM, Reiss DR, Prueksaritanont T, Winrow CJ, Renger JJ. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists. Bioorg Med Chem Lett 2010;20:2311-5. [PMID: 20207138 DOI: 10.1016/j.bmcl.2010.01.138] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
43 German NA, Decker AM, Gilmour BP, Thomas BF, Zhang Y. Truncated Orexin Peptides: Structure-Activity Relationship Studies. ACS Med Chem Lett 2013;4:1224-7. [PMID: 24707347 DOI: 10.1021/ml400333a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
44 Hulme C, Ayaz M, Martinez-ariza G, Medda F, Shaw A. Recent Advances in Multicomponent Reaction Chemistry. In: Czechtizky W, Hamley P, editors. Small Molecule Medicinal Chemistry. Hoboken: John Wiley & Sons, Inc; 2015. pp. 145-87. [DOI: 10.1002/9781118771723.ch6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
45 Yoshida Y, Terauchi T, Naoe Y, Kazuta Y, Ozaki F, Beuckmann CT, Nakagawa M, Suzuki M, Kushida I, Takenaka O, Ueno T, Yonaga M. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists. Bioorg Med Chem 2014;22:6071-88. [PMID: 25267004 DOI: 10.1016/j.bmc.2014.08.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
46 Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66. [PMID: 21034217 DOI: 10.1146/annurev-pharmtox-010510-100528] [Cited by in Crossref: 202] [Cited by in F6Publishing: 194] [Article Influence: 18.4] [Reference Citation Analysis]
47 Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P, Porter RA, Johnson CN, Thewlis K, Donati D, Stasi L, Spada S, Stemp G, Nash D, Branch C, Kindon L, Massagrande M, Poffe A, Braggio S, Chiarparin E, Marchioro C, Ratti E, Corsi M. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorganic & Medicinal Chemistry Letters 2011;21:5562-7. [DOI: 10.1016/j.bmcl.2011.06.086] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
48 Christopher JA. Orexin receptor antagonists. Pharm Pat Anal 2012;1:329-46. [PMID: 24236845 DOI: 10.4155/ppa.12.27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
49 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88. [DOI: 10.1016/j.npep.2013.10.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
50 Sifferlen T, Koberstein R, Cottreel E, Boller A, Weller T, Gatfield J, Brisbare-roch C, Jenck F, Boss C. Synthesis, structure–activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1. Bioorganic & Medicinal Chemistry Letters 2013;23:2212-6. [DOI: 10.1016/j.bmcl.2013.01.088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
51 Rappas M, Ali AAE, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Doré AS, Errey JC, Jazayeri A, Marshall FH, Mason JS, Mould R, Patel JC, Tehan BG, Weir M, Christopher JA. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J Med Chem 2020;63:1528-43. [PMID: 31860301 DOI: 10.1021/acs.jmedchem.9b01787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
52 Benmekhbi L, Louafi F, Roisnel T, Hurvois JP. Synthesis of Tetrahydroisoquinoline Alkaloids and Related Compounds through the Alkylation of Anodically Prepared α-Amino Nitriles. J Org Chem 2016;81:6721-39. [PMID: 27410716 DOI: 10.1021/acs.joc.6b01419] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
53 Boss C, Roch C. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). Expert Opin Ther Pat 2016;26:409-15. [PMID: 26593218 DOI: 10.1517/13543776.2016.1124087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
55 Sifferlen T, Boss C, Cottreel E, Koberstein R, Gude M, Aissaoui H, Weller T, Gatfield J, Brisbare-roch C, Jenck F. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2010;20:1539-42. [DOI: 10.1016/j.bmcl.2010.01.070] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
56 Whitman DB, Cox CD, Breslin MJ, Brashear KM, Schreier JD, Bogusky MJ, Bednar RA, Lemaire W, Bruno JG, Hartman GD, Reiss DR, Harrell CM, Kraus RL, Li Y, Garson SL, Doran SM, Prueksaritanont T, Li C, Winrow CJ, Koblan KS, Renger JJ, Coleman PJ. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 2009;4:1069-74. [PMID: 19418500 DOI: 10.1002/cmdc.200900069] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
57 Nagase H, Yamamoto N, Yata M, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-tomobe Y, Ishikawa Y, Ogawa Y, Hirayama S, Kuroda D, Watanabe Y, Gouda H, Yanagisawa M. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. J Med Chem 2017;60:1018-40. [DOI: 10.1021/acs.jmedchem.6b01418] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
58 Laburthe M, Voisin T, El Firar A. Orexins/hypocretins and orexin receptors in apoptosis: a mini-review. Acta Physiol (Oxf) 2010;198:393-402. [PMID: 19719798 DOI: 10.1111/j.1748-1716.2009.02035.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
59 Cox CD, McGaughey GB, Bogusky MJ, Whitman DB, Ball RG, Winrow CJ, Renger JJ, Coleman PJ. Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding. Bioorg Med Chem Lett 2009;19:2997-3001. [PMID: 19406641 DOI: 10.1016/j.bmcl.2009.04.026] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]